Home › Funds › Farallon Capital Management › BBIO
Farallon Capital Management position in BBIO
BRIDGEBIO PHARMA INC · Health Care
Latest position (Q2 2026)10.74M sh
Reported value held$800.14M
Portfolio Weight3.71%
First reportedQ4 2023
Last changeAdd
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 6.00K | $242.22K | New |
| Q3 2024 | 1.75M | $44.48M | New |
| Q4 2024 | 4.20M | $115.11M | Add |
| Q1 2025 | 5.73M | $198.12M | Add |
| Q2 2025 | 7.90M | $341.12M | Add |
| Q3 2025 | 8.19M | $425.49M | Add |
| Q4 2025 | 9.00M | $688.29M | Add |
| Q1 2026 | 9.37M | $695.48M | Add |
| Q2 2026 | 10.74M | $800.14M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
Other funds holding BBIO
- Vanguard Group 16.86M sh · $1.29B · Q4 2025
- Janus Henderson Group 13.18M sh · $978.61M · Q1 2026
- Viking Global Investors 9.95M sh · $741.02M · Q2 2026
- Two Sigma Investments 4.75M sh · $353.43M · Q2 2026
- D. E. Shaw & Co 3.66M sh · $272.89M · Q2 2026
- Geode Capital Management 3.42M sh · $254.67M · Q2 2026
- Manulife Financial 1.96M sh · $145.66M · Q2 2026
- Charles Schwab Investment Management 1.71M sh · $127.32M · Q2 2026
- Norges Bank Investment Management 1.69M sh · $126.15M · Q2 2026
- Morgan Stanley 1.69M sh · $126.14M · Q2 2026
- Point72 Asset Management 1.53M sh · $114.16M · Q2 2026